
Private Medicare plans must cover Biogen’s ALS drug, US agency says
(Reuters) – The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen (NASDAQ:BIIB)’s amyotrophic lateral sclerosis drug Qalsody after finding instances of coverage denial. Qalsody received the U.S. Food and Drug Administration’s accelerated approval last year, but CMS said it found many Medicare Advantage plans, which cover…